News
AQST
3.320
-4.32%
-0.150
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?
NASDAQ · 1d ago
Aquestive Therapeutics (AQST) Receives a Buy from Lake Street
TipRanks · 2d ago
Aquestive Therapeutics to present new findings at AAAAI meeting
TipRanks · 3d ago
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
Barchart · 3d ago
Weekly Report: what happened at AQST last week (0203-0207)?
Weekly Report · 5d ago
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
Barchart · 02/04 06:00
Weekly Report: what happened at AQST last week (0127-0131)?
Weekly Report · 02/03 11:26
Weekly Report: what happened at AQST last week (0120-0124)?
Weekly Report · 01/27 11:30
Weekly Report: what happened at AQST last week (0113-0117)?
Weekly Report · 01/20 11:20
Promising Pipeline and Solid Financials: Analyst’s Buy Rating on Aquestive Therapeutics
TipRanks · 01/15 07:04
Aquestive Therapeutics: Promising Growth Trajectory with Strategic Initiatives and Strong Market Potential
TipRanks · 01/13 14:05
Lake Street Remains a Buy on Aquestive Therapeutics (AQST)
TipRanks · 01/13 13:56
Aquestive Therapeutics Updates on Strategic Goals and Drug Progress
TipRanks · 01/13 13:14
Aquestive Therapeutics Outlines 2025 Goals, Including Anaphylm Launch and AQST-108 Phase 2a Trial
Benzinga · 01/13 12:50
AQUESTIVE THERAPEUTICS PROVIDES BUSINESS UPDATE AND OUTLINES KEY 2025 OBJECTIVES
Reuters · 01/13 12:00
Weekly Report: what happened at AQST last week (0106-0110)?
Weekly Report · 01/13 11:21
Weekly Report: what happened at AQST last week (1230-0103)?
Weekly Report · 01/06 11:30
Aquestive Therapeutics: Five Foci For 2025
Seeking Alpha · 01/06 05:13
Weekly Report: what happened at AQST last week (1223-1227)?
Weekly Report · 12/30/2024 11:23
Weekly Report: what happened at AQST last week (1216-1220)?
Weekly Report · 12/23/2024 11:30
More
Webull provides a variety of real-time AQST stock news. You can receive the latest news about Aquestive Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.